Overexpression of miR-132-3p inhibits the TGF-<i>β</i>1/Smad2/3 signaling pathway in TGF-<i>β</i>1 induced MET-5A cells. by Yangyang Yin (14323701)

Subjects:

Decreased test sensitivity: Screening the whole population. by Timo de Wolff (9904467)

Supplementary Material for: MicroRNA-125a Correlates with Decreased Psoriasis Severity and Inflammation and Represses Keratinocyte Proliferation by Su F. (4127968)

Inhibition of the mitochondrial fission decreases mtROS production. by Dong Ma (584680)

Subjects:

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). The FMT group also showed a significant reduction in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels from 8.6 to 7.32 mg/L (p = 0.022), while other metabolites showed no significant changes.…”

Video5_Aging, not Parkinson’s disease, decreases a recalibration of body ownership caused by vision-respiratory interaction.MP4 by Daiki Shoji (18283906)

<b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b> by Muhammad Saad Yousuf (20745168)

SARS-CoV-2 inhibits SG formation and decreases expression of G3BP1. by Stacia M. Dolliver (13822801)

Image_5_Evidence for Decreased Density of Calretinin-Immunopositive Neurons in the Caudate Nucleus in Patients With Schizophrenia.TIF by Istvan Adorjan (8466846)

SARS-CoV‑2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity by Mert Golcuk (10789806)

SARS-CoV‑2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity by Mert Golcuk (10789806)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects: